Overcoming Barriers to Use of SGLT2 Inhibitor Therapy: The Battle Against Clinical Inertia

JACC Heart Fail. 2023 Aug;11(8 Pt 1):943-945. doi: 10.1016/j.jchf.2023.05.006. Epub 2023 Jun 14.

Authors

Stephen J Greene¹, Jacob B Pierce²

Affiliations

¹ Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: stephen.greene@duke.edu.
² Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

PMID: 37318416
DOI: 10.1016/j.jchf.2023.05.006

No abstract available

Keywords: Veterans Affairs; cost; guideline-directed medical therapy; heart failure; sodium-glucose cotransporter-2 inhibitor.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Heart Failure*
Humans
Hypoglycemic Agents / therapeutic use
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents